Profound Medical Corp. Income Statement
PROF|2 years of annual SEC 10-K data (FY2024-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 2 fiscal years. All figures from audited SEC 10-K filings.
Profound Medical Corp. reported $11M in revenue and $28M in net loss for FY2025. Revenue increased 48.4% from FY2024 to FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.95 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 |
|---|---|---|
| Revenue | $10.7M | $7.2M |
| Cost of Revenue | $3.6M | $2.9M |
| Gross Profit | $7.0M | $4.3M |
| SG&A Expense | $23.1M | $18.5M |
| R&D Expense | $17.0M | $14.4M |
| Operating Income | -$33.1M | -$28.7M |
| Interest Expense | $600.0K | - |
| Income Tax | -$2.0K | -$128.0K |
| Net Income | -$27.8M | -$28.3M |
| EPS (Basic) | $1.12 | $1.34 |
| EPS (Diluted) | $1.12 | $1.34 |
| Shares Outstanding | 30.0M | 21.4M |
| Gross Margin | 65.9% | 59.9% |
| Operating Margin | -309.6% | -398.0% |
| Profit Margin | -260.4% | -393.4% |